Stefan Schäfer
Disease Group Cardiovascular Diseases
Aventis Pharma
Deutschland GmbH
65926 Frankfurt am Main
Germany
Name/email consistency: high
- Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine. Schäfer, S., Huber, J., Wihler, C., Rütten, H., Busch, A.E., Linz, W. Eur. J. Heart Fail. (2006)
- The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Schäfer, S., Linz, W., Vollert, H., Biemer-Daub, G., Rütten, H., Bleich, M., Busch, A.E. Diabetologia (2004)
- Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction. Schäfer, S., Steioff, K., Linz, W., Bleich, M., Busch, A.E., Löhn, M. Eur. J. Pharmacol. (2004)
- Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Schäfer, S., Schmidts, H.L., Bleich, M., Busch, A.E., Linz, W. Br. J. Pharmacol. (2004)
- Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. Schäfer, S., Kelm, M., Mingers, S., Strauer, B.E. J. Hypertens. (2002)